Table 3 Self-reported generic (EQ-5D) and dermatology-specific (Skindex-17) health-related quality of life in patients with and without cutaneous adverse events associated with DMT
Cutaneous adverse events | |||
|---|---|---|---|
Yes (n = 156) | No (n = 73) | P value* | |
Generic quality of life | |||
EQ-5D utility | |||
median (IQR) | 0.727 (0.620–0.848) | 0.718 (0.664–0.814) | 0.779 |
mean (SD) | 0.725 (0.205) | 0.714 (0.218) | |
EQ-5D VAS | |||
median (IQR) | 70.0 (60.0–80.0) | 75.0 (60.0–80.5) | 0.361 |
mean (SD) | 67.3 (20.9) | 71.7 (15.8) | |
Dermatology-specific quality of life | |||
Skindex-17 Psychosocial | |||
median (IQR) | 1 (0–3) | 0 (0–1) | P < 0.001 |
mean (SD) | 2.2 (3.0) | 1.0 (2.2) | |
Skindex-17 Symptoms | |||
median (IQR) | 2 (1–3) | 1 (0–2) | 0.002 |
mean (SD) | 2.1 (1.7) | 1.5 (1.5) | |